In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development

Area of Science:

• Immunotherapy
• Molecular Biology
• Oncology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy enhances the immune system to fight cancer.
• Traditional viral transfection methods carry risks like insertional oncogenesis and off-target effects.
• In vitro-transcribed (IVT)-mRNA offers a safer alternative by leaving no genetic residue in host cells.

Purpose of the Study:

• To describe the generation of IVT-mRNA for CAR T-cell therapy.
• To detail methods for optimizing CAR IVT-mRNA stability and structure.
• To outline efficient transfection methods for CAR molecule expression on T-cells.

Main Methods:

• Selection of CAR T-cell targets.
• Cloning of templates for in vitro transcription.
• Chemical modifications to enhance CAR IVT-mRNA stability.
• Electroporation and cationic-lipid mediated transfection of CAR IVT-mRNAs.

Main Results:

• The chapter details the IVT-mRNA generation process.
• Optimization strategies for CAR IVT-mRNA structure and stability are presented.
• Efficient transfection methods, electroporation and cationic-lipid mediated, are described.

Conclusions:

• IVT-mRNA represents a safer platform for CAR T-cell immunotherapy.
• The described methods facilitate the generation and delivery of CAR IVT-mRNA.
• This approach holds promise for improving cancer treatment safety and efficacy.